< BACK Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes Jun 27, 2024 Enhancing Mobility and Quality of Life through Agile Co-Designed Exergames for Psoriatic Arthritis We are pleased to announce our latest study, "Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes", presented at PETRA 2024. This research, a part of the Horizon Europe iPROLEPSIS project, focuses on creating Exergames to improve physical activity and well-being for individuals with Psoriatic Arthritis. Abstract Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Here, within the Horizon Europe iPROLEPSIS project that targets Psoriatic Arthritis (PsA), we describe the design process of Exergames to address PsA symptoms, including morning stiffness, impaired finger/hand and wrist functionality, and motor asymmetry. From a methodological point of view, the storyboarding technique was adopted to facilitate the visualization of the proposed Exergame scenarios, including the graphical user interface, interactive game elements, narratives, characters, and contexts related to the PsA condition. This approach has been implemented within an agile game development methodology, which includes gathering feedback early on to iteratively refine both the game ideas and prototype. Informed by the results of the game design via two agile sessions incorporating 25 participants (PsA patients, clinicians, technology developers, facilitators/observers), the current efforts are focused on developing the game prototypes and corresponding mock-ups, preparing them for upcoming clinical validation trials. The Exergames development lays the groundwork for an innovative framework to improve gross and fine motor symptoms in PsA patients. This framework could inform healthcare providers and policymakers about its potential inclusion in routine PsA management. Read more: https://dl.acm.org/doi/10.1145/3652037.3663939 Developing Exergames for Psoriatic Arthritis using Agile .pdf Download PDF • 1.70MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at SportEx during ECSS 2026 Aug 18, 2026 Connecting iPROLEPSIS with the sport science community The European Conference of Sports Science (ECSS) 2026 took place in Lausanne, Switzerland, from 7 to 10 July 2026. As part of the event, SportEx , the official exhibition of ECSS, brought together companies from around the world to showcase innovations in sport science, including wearable technologies, physiological measurement systems, biomechanics, and software solutions. iPROLEPSIS was represented at SportEx by project partner PLUX. This participation helped increase the project’s visibility within the wider sport science community and among stakeholders interested in innovative technologies and digital health. PLUX also showcased its work in biosignal acquisition and wearable technologies, areas closely related to the development of innovative digital health solutions within iPROLEPSIS. IProlepsis 2.jpeg Conference overview 2.jpg Booth 3.jpeg IProlepsis 2.jpeg 1/3 PREVIOUS NEXT

Join iProlepsis project for the psoriatic arthritis community. Share your experience, expertise and observations, observations Community Information will be available soon.

< BACK iPROLEPSIS Website Goes Live Mar 27, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Federated Learning Aggregation based on Weight Distribution Analysis Oct 4, 2023 Enhancing Federated Learning: Leveraging Weight Distribution Analysis for Superior Aggregation Federated learning has recently been proposed as a solution to the problem of using private or sensitive data for training a central deep model, without exchanging the local data. In federated learning, local models are trained on the client side using the available data, while a server is responsible for aggregating the weights of these models into a global model. However, the traditional weight averaging approach does not take into consideration the importance of the different weights for the performance of a model. To this end, this work proposes a novel federated learning weight aggregation method that estimates the statistical distance of each client's parameters from the Gaussianity, and weighs the contribution of each client to the global model accordingly so that the most significant information is retained and enhanced. To create an accurate global model, a complex weighted averaging of the parameters of clients' models at the layer level is performed, considering as low quality the parameters following the Gaussian distribution. The proposed method can be employed to both convolutional and linear layers and it is based on the notion that parameters following a Gaussian distribution do not significantly affect the output of a model. Experiments with different network architectures and a comparison with a plethora of state-of-the-art approaches on three well-known image classification datasets demonstrate the superiority of the proposed method for federated learning weight aggregation. Read the full publication: https://www.researchgate.net/publication/374440973_Federated_Learning_Aggregation_based_on_Weight_Distribution_Analysis 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the 15th Portuguese Rheumatology Congress Oct 27, 2023 iPROLEPSIS project and iPROLEPSIS-PDPID study presented at the 15th Portuguese Rheumatology Congress On October 27, 2023, the Portuguese Society of Rheumatology (SPR) , a dedicated partner of iPROLEPSIS , took the stage at the 15th Portuguese Rheumatology Congress (XXV Congresso Português de Reumatologia) , the event attended by around 700 individuals, mainly rheumatologists and GPs. Cátia Gonçalves, Reuma.pt Study Coordinator, and Ana M. Rodrigues, Reuma.pt National Coordinator and Assistant Professor at NOVA Medical School, provided a comprehensive overview of the iPROLEPSIS project, its goals, and clinical studies. They also introduced the iPROLEPSIS-PDPID study , focusing on PsA digital phenotyping and inflammation drivers. Portuguese Rheumatology centres were invited to participate in the iPROLEPSIS-PDPID study, marking a significant step in advancing our research. News & Events iPROLEPSIS.png News & Events iPROLEPSIS.png 1/1 PREVIOUS NEXT

< BACK Understanding Enthesitis in Psoriatic Arthritis Oct 7, 2024 iPROLEPSIS presented in the 16th Panhellenic Conference of EPEMY Aristotle University of Thessaloniki presented iPROLEPSIS in the 16th Panhellenic Conference of EPEMY held in Ioannina, Greece, from 3-6 October 2024. The presentation addressed important topics related to nesting, the role of enthesitis in Psoriatic Arthritis and Axial Spondyloarthritis, and the most appropriate treatment approaches for enthesitis and digitalis. This conference focused on inflammatory and autoimmune rheumatic, gastrointestinal, and skin diseases, as well as osteoporosis and osteoarthritis. Individual sessions covered Covid-19, cancer, neurological syndromes, and co-morbidities. The event emphasised clinically applied treatments, with interactive, cross-company tutorials and presentations of research projects from domestic centers, which were awarded for their contributions. Read more about the conference here . 1/1 PREVIOUS NEXT

< BACK Understanding Patient Perspectives on Digital Biomarkers for Psoriatic Arthritis Nov 28, 2024 A new study explores opportunities and challenges in using digital biomarkers for Psoriatic Arthritis management A recently published study, Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers , examines how patients with Psoriatic Arthritis (PsA) perceive the use of digital biomarkers (dBMs) in managing their condition. With the increasing use of wearables like smartphones and smartwatches, there is growing interest in utilizing these tools to track physiological and behavioral data in everyday life. This study, involving 27 PsA patients across six focus groups, sheds light on the potential benefits and limitations of integrating dBMs into PsA care. Key Insights The study identified three main areas of interest: Opportunities: Patients saw value in using digital biomarkers to track early signs of disease flare-ups and monitor symptoms over time. Disease Activity Mapping: Participants highlighted the importance of using a broad range of data points to reflect the complexity of PsA symptoms. Barriers: Concerns about privacy, data security, and maintaining strong connections with healthcare providers were key considerations for patients. Relevance to iPROLEPSIS The findings align with iPROLEPSIS’s goal of integrating patient-centered digital health tools into chronic disease management. This study offers important guidance on ensuring digital health innovations address real-world patient needs while maintaining trust and usability. e004699.full .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT

< BACK Insights from iPROLEPSIS 4th Plenary meeting Jul 3, 2024 iPROLEPSIS Plenary Meeting 2024 Recap The 4th iPROLEPSIS plenary meeting took place on 1-2 July 2024 in Munich, Germany, drawing partners from across Europe. The focus was on discussing progress updates and planning future actions towards developing a novel personalised digital care ecosystem for people with Psoriatic Arthritis (PsA). Agenda included: WP overviews, updates and planning next steps General Assembly & External Advisory Board sessions Workshop on : - IDBV (Inflammation digital biomarkers validation study) study: Overview of outcomes, data collection decisions, next steps; - PPIDC (Prevention of PsA inflammation through digital care: an intervention study) study: Objectives, cohort characteristics, study design. WP3 research activities and upcoming deliverables; - iPROLEPSIS ecosystem co-creation, usage scenarios identification, requirements definition; - Serious games co-creation: Introduction to iPROLEPSIS Games app, demonstrations, interactive feedback session. Special Acknowledgment: Gratitude to our patient partners who joined the Serious Games co-creation workshop online and provided valuable insights, ensuring our solutions are truly patient-centric. 1/10 PREVIOUS NEXT

< BACK European Researchers' Night Sep 30, 2024 Engaging Communities through Science Bárbara Ramalho, Hugo Escobar, and Marta Vicente from FMH/IST-ULisboa presented the iPROLEPSIS Games and the iPROLEPSIS project at the European Researchers' Night in Oeiras, Portugal. This event, part of the "Science for Everyone (SCIEVER) – Inclusion and Sustainability" initiative, aimed to engage the public with scientific advancements. Researchers from various fields participated, sharing their work through interactive presentations, live demonstrations, and diverse activities, fostering a stronger connection between science and the community. The event unerlined the importance of making scientific research accessible to all. 1/4 PREVIOUS NEXT

iProlepsis project for psoriatic arthritis uses multi-source data analysis for guiding to a novel personalised digital care ecosystem and maximizes the impact. iPROLEPSIS project vision and impact maximisation Health-to-PsA transition through multi-source data analysis guiding to a novel personalised digital care ecosystem and impact maximisation through openness, visibility, networking and reuse of outcomes. Project vision Data analysis, iPROLEPSIS project goals, IoT technologies and mobile application. About Psoriatic Arthritis Psoriatic Arthritis (PsA) is a chronic, inflammatory disease, affecting the peripheral and axial skeleton, with a severe impact on patients’ quality-of-life. It is estimated that 1-2% of the general population has PsA, i.e., 5 to 10 million people in EU are affected . PsA is associated with psoriasis (PsO) and up to 30% of people living with PsO, i.e., at least 100 million people worldwide (WHO), are expected to develop PsA. The goal The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real Worl Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. Technologies IoT sensing technologies and a mobile application will be at the heart of the RWD collection procedure, while retrospective and prospective multi-source data will be collected from the clinical partners’ databases, combined with open access ones. Through the analysis and visualisation of these data using AI predictive models and an intuitive visual analytics tool, respectively, the iPROLEPSIS will be able to propose personalized treatments (i.e., diet, physical activity, stress/fatigue/pain management), assisting doctors, caregivers, and hospitals towards the optimal management of PsA. Finally, through xAI techniques, iPROLEPSIS aims to facilitate hospitals and policy makers in gaining new insights towards better clinical practices, thus shaping future PsA treatment policies. Impact maximisation To ensure the successful implementation of the pathways towards impact in long-term, the project consortium aims at making iPROLEPSIS a reference for the fight against PsA by: 01 Creating an active iPROLEPSIS community of stakeholders. 02 Informing key stakeholders about results and their clinical innovation potential. 03 Making the outputs widely available for research and business purposes in the long term. 04 Increasing people with/at risk of PsA engagement for addressing their issues and concerns in order to increase their awareness and to build trust into new technology. 05 Reaching similar/relevant R&I projects for promoting networking and joint activities. 06 Establishing a forum/community for HCPs and authorities to develop new guidelines and standards. 07 Identifying exploitation mechanisms and activities, assessing the commercialization and applicability of the concepts and ideas. PROJECT OBJECTIVES

< BACK iPROLEPSIS Newsletter No. 6 Oct 9, 2024 Latest News from iPROLEPSIS Welcome to the 6th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_October 2024_ Issue No. 6 .pdf Download PDF • 4.41MB 1/1 PREVIOUS NEXT